Abstract:Tuberculosis (TB), caused by the airborne bacterial pathogen Mycobacterium tuberculosis, remains a major source of morbidity and mortality worldwide. So far, the study of host-pathogen interactions in TB has mostly focused on the physiology and virulence of the pathogen, as well as, on the various innate and adaptive immune compartments of the host. Microbial organisms endogenous to our body, the so-called microbiota, interact not only with invading pathogens, but also with our immune system. Yet, the impact of the microbiota on host defense against M. tuberculosis remains poorly understood. In order to address this question, we adapted a robust and reproducible mouse model of microbial dysbiosis based on a combination of wide-spectrum antibiotics. We found that microbiota dysbiosis resulted in an increased early colonization of the lungs by M. tuberculosis during the first week of infection, correlating with an altered diversity of the gut microbiota during this time period. At the cellular level, no significant difference in the recruitment of conventional myeloid cells, including macrophages, dendritic cells and neutrophils, to the lungs could be detected during the first week of infection between microbiota-competent and -deficient mice. At the molecular level, microbiota depletion did not impact the global production of pro-inflammatory cytokines, such as interferon (IFN)γ, tumor necrosis factor (TNF)α and interleukin (IL)-1β in the lungs. Strikingly, a reduced number of mucosal-associated invariant T (MAIT) cells, a population of innate-like lymphocytes whose development is known to depend on the host microbiota, was observed in the lungs of the antibiotics-treated animals after 1week of infection. These cells produced less IL-17A in antibiotics-treated mice. Notably, dysbiosis correction through the inoculation of a complex microbiota in antibiotics-treated animals reversed these phenotypes and improved the ability of MAIT cells to proliferate. Altogether, our results demonstrate that the host microbiota contributes to early protection of lung colonization by M. tuberculosis, possibly through sustaining the function(s) of MAIT cells. Our study calls for a better understanding of the impact of the microbiota on host-pathogen interactions in TB. Ultimately, this study may help to develop novel therapeutic approaches based on the use of beneficial microbes, or components thereof, to boost anti-mycobacterial immunity.

The Role of Gut and Lung Microbiota in Susceptibility to Tuberculosis

Impact of the gut-lung axis on tuberculosis susceptibility and progression

Altered Intestinal Microbiota and Fecal Metabolites in Patients with Latent and Active Pulmonary Tuberculosis

Gut microbiota: a crucial player in the combat against tuberculosis

The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment

Mycobacterium tuberculosis, antimicrobials, immunity, and lung-gut microbiota crosstalk: current updates and emerging advances

Microbiota and Tuberculosis: A Potential Role of Probiotics, and Postbiotics

The gut microbiome in tuberculosis susceptibility and treatment response: guilty or not guilty?

The gut microbiota mediates protective immunity against tuberculosis via modulation of lncRNA

Lung and Gut Affair

The Host Microbiota Contributes to Early Protection Against Lung Colonization by Mycobacterium tuberculosis

The role of Mycobacterium tuberculosis exosomal miRNAs in host pathogen cross-talk as diagnostic and therapeutic biomarkers

Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis

The lung microbiome: clinical and therapeutic implications

Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment

Research Progress on Genetic Control of Host Susceptibility to Tuberculosis.

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases

Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis

Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents

Impact of Lung Microbiota on COPD

Tuberculosis Diagnosis: Current, Ongoing, and Future Approaches